A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma

20250 citationsJournal Articlehybrid Open Access

Authors

Anthony B. El-Khoueiry · University of Southern California

Richard D. Kim · Moffitt Cancer Center

William Proctor Harris · Fred Hutch Cancer Center

Max W. Sung · Tisch Hospital

Dirk Waldschmidt · University Hospital Cologne

Roniel Cabrera · University of Florida

Vittorio Luigi Garosi

Abstract

Treatment with rego/pembro is feasible in patients with advanced HCC with a manageable safety profile. ORR and DCR are promising and consistent with other immunotherapy combinations in this setting.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Cancer Immunotherapy and Biomarkers Liver physiology and pathology

Publication Details

Published in: Hepatology

DOI: 10.1097/hep.0000000000001585

Field-Weighted Citation Impact: 0.00

Command Palette

A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma

Authors

Abstract

Topics & Keywords

Publication Details